According to a recent study that was carried out by the National Center for Biotechnology Information, there has been a steady growth in the numbers of incidence of GERD in the Asia Pacific. The APAC region market for GERD drugs and devices account growth of 1.52% CAGR through the forecasted years of 2019-2027. Japan, China and India are the largest revenue contributor to the APAC market for GERD drugs and devices.

ASIA PACIFIC GERD DRUGS AND DEVICES MARKET FORECAST 2019-2027

According to a recent study that was carried out by the National Center for Biotechnology Information, there has been a steady growth in the numbers of incidence of GERD in the Asia Pacific. The APAC region market for GERD drugs and devices account growth of 1.52% CAGR through the forecasted years of 2019-2027.

Japan, China and India are the largest revenue contributor to the APAC market for GERD drugs and devices. Availability of fewer approved drugs to treat GERD and increasing awareness about GERD among the patients are the drivers that are propelling the said market in the APAC region. These countries account for a large part of the world population. For instance, Japan is one of those countries with almost balanced economic harmony, also has a large geriatric population who are more susceptible to GERD and gastric influx. So, the market growth and revenue contribution are much higher for Japan than others.

Some of the leading companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • ANTACIDS DRUG CLASS HOLDS THE LARGEST MARKET SHARE
        • BRAVO SYSTEM DEVICES ARE WIDELY USED
    1. MARKET DYNAMICS
      • MARKET SCOPE & DEFINITION
      • MARKET DRIVERS
        • GROWING TREND OF SELF-MEDICATION
        • INCREASING AWARENESS ABOUT GERD
        • INCREASING OCCURRENCE OF GERD DISORDERS
        • CHANGES IN LIFESTYLE
      • MARKET RESTRAINTS
        • PATENT EXPIRY
        • ADVERSE EFFECT OF PROTON PUMP INHIBITORS AND OTHER DRUGS
        • PROTON PUMP INHIBITOR RESISTANCE
      • MARKET OPPORTUNITIES
        • INCREASED PRACTICE OF GENERICS AND OTC DRUGS
        • COST-EFFECTIVE OTC DRUGS
        • OVERUSE OF MEDICATION AND DIETARY SUPPLEMENTS
      • MARKET CHALLENGES
        • USE OF COMPLEMENTARY AND ALTERNATIVE TREATMENTS
        • PROBABILITY OF BUYING COUNTERFEIT DRUGS
      • MARKET BY DRUGS DOSAGE FORM
      • MARKET BY ROUTE OF ADMINISTRATION OF DRUGS
    2. MARKET BY DRUGS AND DEVICES
      • DRUG CLASS
        • ANTACIDS
        • H2 RECEPTOR BLOCKERS
        • PROTON PUMP INHIBITORS (PPI)
        • PRO-KINETIC AGENTS
      • DEVICES
        • DIGITRAPPER
        • BRAVO SYSTEM
        • STRETTA
        • LINX REFLUX MANAGEMENT SYSTEM
        • MUSE (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM
        • OTHER DEVICES
    1. KEY ANALYTICS
      • PORTER’S FIVE FORCE MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • PIPELINE DRUGS
      • REGULATORY FRAMEWORK
      • PATENT ANALYSIS
      • OPPORTUNITY MATRIX
    2. GEOGRAPHICAL ANALYSIS
      • ASIA PACIFIC
        • JAPAN
        • CHINA
        • INDIA
        • AUSTRALIA
        • SOUTH KOREA
        • REST OF ASIA PACIFIC
    1. COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
      • COMPANY PROFILES
        • ABBOTT LABORATORIES.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • ASTRAZENECA
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BAUSCH HEALTH (FORMERLY VALEANT PHARMACEUTICALS INTERNATIONAL, INC.)
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • BOSTON SCIENTIFIC CORPORATION
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • CEMPRA INC. (MERGED WITH MELINTA)
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • DAEWOONG CO. LTD.
          • COMPANY PROFILES
          • PRODUCT PORTFOLIO
          • STRATEGIC INITIATIVES
        • EISAI INC
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • GLAXOSMITHKLINE
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • IRONWOOD PHARMACEUTICALS, INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • JOHNSON & JOHNSON
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • MERCK & CO., INC.
          • COMPANY PROFILES
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • NOVARTIS
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • PFIZER, INC.
          • COMPANY PROFILES
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES
        • RAQUAL IA PHARMA INC.
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • STRATEGIC INITIATIVES
        • TAKEDA PHARMACEUTICALS COMPANY LIMITED
          • COMPANY OVERVIEW
          • PRODUCT PORTFOLIO
          • SCOT ANALYSIS
          • STRATEGIC INITIATIVES

    LIST OF TABLES

    TABLE 1       ASIA PACIFIC GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    TABLE 2       ASIA PACIFIC GERD DRUGS AND DEVICES MARKET BY DRUGS AND DEVICES 2019-2027 ($ MILLION)

    TABLE 3       ASIA PACIFIC DRUG CLASS MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 4       ASIA PACIFIC DRUG CLASS MARKET 2019-2027 ($ MILLION)

    TABLE 5       ASIA PACIFIC ANTACIDS MARKET 2019-2027 ($ MILLION)

    TABLE 6       ASIA PACIFIC H2 RECEPTOR BLOCKERS MARKET 2019-2027 ($ MILLION)

    TABLE 7       ASIA PACIFIC H2 RECEPTOR BLOCKERS MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 8       ASIA PACIFIC PROTON PUMP INHIBITORS (PPI) MARKET 2019-2027 ($ MILLION)

    TABLE 9       ASIA PACIFIC PROTON PUMP INHIBITORS (PPI) MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 10     ASIA PACIFIC PRO-KINETIC AGENTS MARKET 2019-2027 ($ MILLION)

    TABLE 11     ASIA PACIFIC DEVICES MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 12     ASIA PACIFIC DEVICES MARKET 2019-2027 ($ MILLION)

    TABLE 13     ASIA PACIFIC DIGITRAPPER MARKET 2019-2027 ($ MILLION)

    TABLE 14     ASIA PACIFIC BRAVO SYSTEM MARKET 2019-2027 ($ MILLION)

    TABLE 15     ASIA PACIFIC STRETTA (MEDERITHERAPEUTICS) MARKET 2019-2027 ($ MILLION)

    TABLE 16     ASIA PACIFIC LINX® REFLUX MANAGEMENT SYSTEM (TORAX MEDICAL) MARKET 2019-2027 ($ MILLION)

    TABLE 17     ASIA PACIFIC MUSE™ (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM MARKET 2019-2027 ($ MILLION)

    TABLE 18     ASIA PACIFIC OTHER DEVICES MARKET 2019-2027 ($ MILLION)

    TABLE 19     ASIA PACIFIC GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    TABLE 20     ASIA PACIFIC GERD DRUGS AND DEVICES MARKET BY COUNTRY 2019-2027 ($ MILLION)

    LIST OF FIGURES

    FIGURE 1     ASIA PACIFIC GERD DRUGS AND DEVICES MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

    FIGURE 2     ASIA PACIFIC GERD DRUGS AND DEVICES MARKET SHARE BY DRUGS AND DEVICES 2017 & 2027 (%)

    FIGURE 3     PORTER’S FIVE FORCE MODEL

    FIGURE 4     ASIA PACIFIC GERD DRUGS AND DEVICES MARKET REGIONAL OUTLOOK 2018 & 2027 (%)

    FIGURE 5     JAPAN GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    FIGURE 6     CHINA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    FIGURE 7     INDIA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    FIGURE 8     AUSTRALIA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    FIGURE 9     SOUTH KOREA GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    FIGURE 10   REST OF ASIA PACIFIC GERD DRUGS AND DEVICES MARKET 2019-2027 ($ MILLION)

    FIGURE 11   GERD PPIS DRUGS PROVIDER COMPANY MARKET SHARE 2017 (%)

    1. GEOGRAPHICAL ANALYSIS
      • ASIA PACIFIC
        • JAPAN
        • CHINA
        • INDIA
        • AUSTRALIA
        • SOUTH KOREA
        • REST OF ASIA PACIFIC
    1. MARKET BY DRUGS AND DEVICES
      • DRUG CLASS
        • ANTACIDS
        • H2 RECEPTOR BLOCKERS
        • PROTON PUMP INHIBITORS (PPI)
        • PRO-KINETIC AGENTS
      • DEVICES
        • DIGITRAPPER
        • BRAVO SYSTEM
        • STRETTA
        • LINX REFLUX MANAGEMENT SYSTEM
        • MUSE (MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER) SYSTEM
        • OTHER DEVICES

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type